The strangest thing about a transplanted organ is that it can leave breadcrumbs in the bloodstream. When cells from a donor kidney, heart, or lung are injured, fragments of donor-derived cell-free DNA may appear in the recipient's blood. CareDx built a business around reading those crumbs before trouble becomes obvious. Its blood tests do not make the drama of transplant disappear. They give clinicians another way to decide when the patient needs closer attention - and when an invasive biopsy might not be the first move.
That idea now sits inside a much larger machine. CareDx sells molecular testing, transplant-center software, patient support, and specialty pharmacy services. It says it has performed more than one million rejection-monitoring tests, fills roughly 150,000 prescriptions a year through its transplant pharmacy, and has at least one software product in about 70 percent of transplant centers. In 2025, the Brisbane, California company generated $379.8 million in revenue.
This is not a mass-market wellness company wearing a lab coat. Its users are transplant physicians, coordinators, quality teams, pharmacists, researchers, and people living with someone else's organ. Its advantage comes from being unusually specific. CareDx knows the handful of institutions that do this difficult work, the clinical evidence those institutions expect, and the administrative thicket around getting a test ordered, performed, interpreted, and paid for.
One blood draw, two different stories
CareDx's oldest commercial anchor is AlloMap Heart. Cleared by the FDA in 2008, AlloMap measures the expression of genes associated with immune activity. In eligible heart-transplant recipients, a low score can help identify a low probability of moderate or severe acute cellular rejection when considered with the rest of the clinical picture. The point is not that a vial of blood magically knows everything. The point is that a useful negative signal can spare selected patients from routine tissue sampling.
AlloSure looks at a different signal: donor-derived cell-free DNA. A higher fraction can indicate injury to a transplanted organ, although injury is not the same thing as a complete diagnosis. CareDx launched AlloSure Kidney commercially in October 2017 after securing Medicare coverage. HeartCare combines AlloMap and AlloSure for heart recipients, placing immune activation and graft injury on the same report.
The distinction matters. Blood-based surveillance is most compelling when it reduces needless procedures without pretending tissue has become obsolete. In the randomized IMAGE study, selected heart-transplant patients monitored with gene-expression profiling had non-inferior clinical outcomes to those monitored with routine biopsy and underwent substantially fewer biopsies. CareDx's own use materials are equally plain about the boundary: results belong beside symptoms, history, examination, and other findings. An abnormal result may lead to a biopsy, not cancel one.
The biopsy captures a moment. CareDx built a business around the years between moments.The useful strategic insight02 / The machine
The test opens the door. Workflow keeps it open.
A transplant is a procedure followed by a lifetime of management. CareDx gradually followed that timeline outward. It acquired Ottr and XynManagement in 2019, adding transplant patient-management and quality-reporting software. In 2021 came TransChart, medication-management company MedActionPlan, a patient app, and The Transplant Pharmacy. The pieces help centers manage referrals, track wait-list patients, document outcomes, coordinate prescriptions, and keep patients on schedule.
Move referrals between nephrology, dialysis, and transplant programs.
Run clinical workflow, quality tracking, and reporting.
Add longitudinal molecular signals after transplant.
Coordinate medication, education, testing, and follow-up.
That portfolio explains the business model. Testing services are paid mainly through Medicare and commercial insurance. Pharmacy contributes product and service revenue. Software brings subscriptions, implementation, and support. But the more interesting economic feature is channel reuse. There are only so many transplant programs. Once CareDx earns trust inside one, a new product can travel through an existing commercial relationship instead of starting cold in a new specialty.
Competitors can match pieces of this stack. Natera's Prospera and Eurofins Viracor's TRAC compete in donor-derived cell-free DNA testing. Hospital labs can develop tests, and biopsy remains the familiar clinical reference. Software faces internal systems and specialized vendors. CareDx's difference is the bundle plus the focus: molecular evidence, workflow, patient contact, and a commercial team aimed at the same concentrated customer set.
03 / The fractureWhat failed first was not the science
In 2023, the dependency hiding underneath the model became visible. Medicare billing-article changes hurt testing-services revenue. Total revenue fell 13 percent, from $321.8 million in 2022 to $280.3 million. The fourth quarter carried a $96.3 million litigation accrual tied to a patent verdict, and the company finished the year with a $118.1 million quarterly net loss. Leadership described a reset: reduce the cost structure, stabilize operations, and find a path back to growth.
The 2023 billing shock interrupted growth. Volume, reimbursement, pharmacy, and digital adoption then helped rebuild it.
The important cost was not one tidy invoice. It was a year of lower revenue, restructuring, leadership transition, and expensive legal uncertainty. In April 2024, John Hanna became chief executive with an explicit brief to produce sustainable, profitable growth. By 2025, revenue had reached $379.8 million, operating cash flow was $42 million, and adjusted EBITDA was $32 million, although the company still reported a $21 million GAAP net loss.
What changed management's mind about the shape of the company is clearest in two 2026 deals. CareDx sold its lab-products business to Eurobio Scientific for $170 million in cash, simplifying the operation and retaining exclusive North American rights to distribute certain post-transplant monitoring kits. Then it bought Naveris for $160 million upfront, with up to $100 million more tied to revenue milestones.
Naveris makes NavDx, a Medicare-covered blood test for molecular residual disease in HPV-driven head-and-neck and anal cancers. It had reported more than 130,000 commercial tests and about $35 million of 2025 revenue. This was not random diversification. In Hanna's formulation, CareDx wants category-leading, repeat molecular biomarkers for patients carrying a high burden of disease. Transplant remains the template; specialty oncology is the next application.
04 / The copyable bitSteal the architecture, not the medical claim
Five moves worth copying
- Choose a narrow beachhead. Deep expertise can beat a broad pitch when the buyers know one another and the problem is costly.
- Build for repetition. A longitudinal test creates more learning and more customer value than a one-off transaction.
- Treat evidence as product work. Clinical studies, guidelines, and coverage are part of adoption, not paperwork after launch.
- Own the handoffs. Software, pharmacy, and patient support make the core insight easier to use in ordinary clinical life.
- Prune with a thesis. Sell an adjacent business when capital and attention can reinforce the central model elsewhere.
The temptation is to copy the bundle immediately. That gets the sequence backward. CareDx spent years validating a clinical wedge before surrounding it with services. A weak core product plus five adjacent dashboards is merely a more complicated weak product. The transferable move is to earn the right to expand through evidence and repeated use.
Specialized care, repeat decisions, concentrated buyers, measurable outcomes, high switching friction, and reimbursement that rewards demonstrated utility.
One-time use, scattered buyers, ambiguous action after a result, weak payer coverage, poor workflow fit, or expansion into markets where the original channel offers no advantage.
Can transplant discipline survive oncology ambition?
CareDx enters its next chapter with sharper numbers and fresh risk. Second-quarter 2026 revenue rose 52 percent to $132 million, helped by testing growth, favorable reimbursement, and prior-period revenue. Management raised full-year guidance to $490 million-$500 million. Medicare also finalized coverage parameters for kidney, heart, and lung molecular surveillance, offering something every diagnostics operator prizes: clearer rules.
But the model is conditional. A molecular signal must change a useful clinical decision. Evidence has to survive scrutiny beyond company-sponsored slides. Coverage can change. A concentrated market lowers acquisition cost but magnifies the effect of a payer decision or an aggressive competitor. Oncology brings new physicians, workflows, and evidence standards. Naveris fits the repeat-testing thesis; integration still has to make the thesis true.
The amusing arc is that a company born in 1998 as Hippocratic Engineering took nearly three decades to discover its cleanest corporate sentence. It is not simply “the transplant company,” and it is not a shopping cart of diagnostics. It is trying to become the company for repeated molecular decisions in diseases where waiting for visible damage is a rotten plan. CareDx's best lesson is similarly plain: find the smallest market in which being indispensable can compound, then keep earning the next test.